European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

Call for experts: International survey on radioligand therapy and theranostics

Radioligand therapy (RLT) and theranostics are rapidly gaining recognition as transformative approaches in cancer management, offering highly targeted treatment options for patients. To understand and prepare for this evolving landscape, the OECD Nuclear Energy Agency (NEA) is conducting an international survey to gather expert insights on the current status of radioligand therapy (RLT) and its integration into cancer care, while also forecasting future demand.

Mon, 6 Oct 2025
Radioligand TherapyNuclear Energy AgencyEuropean Association Of Nuclear MedicineRadioligand Imaging

Dr. Jochen Walz (FR), who serves as the EAU’s contact person to the European Association of Nuclear Medicine (EANM) shares insights on this research and highlights the importance of urologists participating in these surveys to support the implementation of international strategies for patient access to RLT. Recently, the EAU and the EANM signed a Memorandum of Understanding (MoU) to strengthen cross-disciplinary collaboration in cancer care.

According to Prof. Walz, the NEA project has four main objectives: 

  1. Estimate the number of eligible patients for RLT over the next 10-15 years.
  2. Assess healthcare system readiness such as infrastructure, workforce, regulations, and funding challenges.
  3. Secure the supply of key therapeutic radioisotopes, such as Lutetium-177 and Actinium-225.
  4. Develop evidence-based recommendations to the 38 OECD member countries to ensure timely and equitable access to RLT and theranostics.

Prof. Walz emphasises why this research matters: “Such projects raise awareness about RLT by addressing the most pressing questions. They also provide a cross-sectional view of the situation in many countries, highlighting availability, bottlenecks, and opportunities for improvement.”  

How to participate in the surveys

Nuclear Energy Agency (NEA) - Survey: Current status of radioligand therapy and patient eligibility

Survey 1 – Current status of RLT and RLI

Current status of RLT
This survey collects information on the clinical use, therapeutic efficacy, innovation pipelines, and healthcare system readiness for delivering RLT and Radioligand Imaging (RLI).


Surveys 2 & 3 – Patient eligibility for RLT

Patient eligibility for RLT part1

Patient eligibility for RLT part2

These surveys aim to estimate the number of patients eligible for RLT, including those eligible under emerging radiopharmaceutical approaches, to help forecast future demand.

Responses are invited from experts on behalf of their country, region, or institution. Even approximate data, or qualitative assessments are welcome, as the NEA seeks to build as comprehensive a picture as possible. The results will contribute to an official OECD/NEA publication, currently planned for release in late-2026.

Deadline for survey submission is 15 October 2025. For more information, you can contact via the OECD NEA.

Participate in the OECD NEA Survey

Share this article

Suggested for you

See all

There are no news articles related to this page right now. See all news articles

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer